Literature DB >> 20561068

DHE repression of ATP-mediated sensitization of trigeminal ganglion neurons.

Caleb G Masterson1, Paul L Durham.   

Abstract

OBJECTIVE: To investigate the mechanism by which adenosine triphosphate (ATP) causes sensitization of trigeminal neurons and how dihydroergotamine (DHE) represses this modulatory effect.
BACKGROUND: Dihydroergotamine is an effective treatment of migraine. The cellular mechanisms of action of DHE in treating migraine attacks remain unclear.
METHODS: In this study, neonatal rat trigeminal ganglia cultures were used to investigate effects of ATP, alpha, beta-methyl ATP (α,β-meATP), and DHE on intracellular calcium levels and calcitonin gene-related peptide (CGRP) secretion.
RESULTS: Pretreatment with ATP or α,β-meATP caused sensitization of neurons, via P2X(3) receptors, such that a subthreshold amount of potassium chloride (KCl) significantly increased intracellular calcium levels and CGRP secretion. Pretreatment with DHE repressed increases in calcium and CGRP secretion in response to ATP-KCl or α,β-meATP-KCl treatment. Importantly, these inhibitory effects of DHE were blocked with an α(2) -adrenoceptor antagonist and unaffected by a 5HT(1B/D) receptor antagonist. DHE also decreased neuronal membrane expression of the P2X(3) receptor.
CONCLUSIONS: Our findings provide evidence for a novel mechanism of action for DHE that involves blocking ATP-mediated sensitization of trigeminal neurons, repressing stimulated CGRP release, and decreasing P2X(3) membrane expression via activation of α(2) -adrenoceptors.
© 2010 American Headache Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20561068      PMCID: PMC3138143          DOI: 10.1111/j.1526-4610.2010.01714.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  61 in total

Review 1.  Molecular physiology of P2X receptors and ATP signalling at synapses.

Authors:  B S Khakh
Journal:  Nat Rev Neurosci       Date:  2001-03       Impact factor: 34.870

Review 2.  The role of mast cells in migraine pathophysiology.

Authors:  Theoharis C Theoharides; Jill Donelan; Kristiana Kandere-Grzybowska; Aphrodite Konstantinidou
Journal:  Brain Res Brain Res Rev       Date:  2005-07

Review 3.  P2X3 receptor involvement in pain states.

Authors:  Kerstin Wirkner; Beata Sperlagh; Peter Illes
Journal:  Mol Neurobiol       Date:  2007-07-17       Impact factor: 5.590

4.  Tumor necrosis factor-alpha stimulation of calcitonin gene-related peptide expression and secretion from rat trigeminal ganglion neurons.

Authors:  Elizabeth J Bowen; Thomas W Schmidt; Christina S Firm; Andrew F Russo; Paul L Durham
Journal:  J Neurochem       Date:  2005-11-08       Impact factor: 5.372

5.  Pharmacological diversity between native human 5-HT1B and 5-HT1D receptors sited on different neurons and involved in different functions.

Authors:  M Marcoli; G Maura; C Munari; A Ruelle; M Raiteri
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

6.  Venoconstrictor responses to dihydroergocristine and dihydroergotamine: evidence for the involvement of 5-HT1 like receptors.

Authors:  E Müller-Schweinitzer
Journal:  Cardiovasc Drugs Ther       Date:  1990-12       Impact factor: 3.727

7.  Observations on the algogenic actions of adenosine compounds on the human blister base preparation.

Authors:  Tirza Bleehen; C A Keele
Journal:  Pain       Date:  1977-08       Impact factor: 6.961

8.  siRNA relieves chronic neuropathic pain.

Authors:  Gabriele Dorn; Sadhana Patel; Glen Wotherspoon; Maja Hemmings-Mieszczak; Jane Barclay; Francois J C Natt; Pierre Martin; Stuart Bevan; Alyson Fox; Pam Ganju; William Wishart; Jonathan Hall
Journal:  Nucleic Acids Res       Date:  2004-03-16       Impact factor: 16.971

9.  alpha 2-Adrenoreceptor-mediated inhibition of acetylcholine-induced noradrenaline release from rat sympathetic neurons: an action at voltage-gated Ca2+ channels.

Authors:  S Boehm; S Huck
Journal:  Neuroscience       Date:  1995-11       Impact factor: 3.590

10.  Early intervention with almotriptan improves sustained pain-free response in acute migraine.

Authors:  Ninan T Mathew
Journal:  Headache       Date:  2003 Nov-Dec       Impact factor: 5.887

View more
  8 in total

Review 1.  Acute treatment of migraines.

Authors:  Arnaldo N Da Silva; Stewart J Tepper
Journal:  CNS Drugs       Date:  2012-10-01       Impact factor: 5.749

Review 2.  Migraine Treatment: Current Acute Medications and Their Potential Mechanisms of Action.

Authors:  Jonathan Jia Yuan Ong; Milena De Felice
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

3.  MAP0004, orally inhaled dihydroergotamine for acute treatment of migraine: efficacy of early and late treatments.

Authors:  Stewart J Tepper; Shashidhar H Kori; Peter J Goadsby; Paul K Winner; Min H Wang; Stephen D Silberstein; F Michael Cutrer
Journal:  Mayo Clin Proc       Date:  2011-10       Impact factor: 7.616

4.  Advances in drug development for acute migraine.

Authors:  Ryan J Cady; Candace L Shade; Roger K Cady
Journal:  Drugs       Date:  2012-12-03       Impact factor: 9.546

Review 5.  Ion channels and migraine.

Authors:  Jin Yan; Gregory Dussor
Journal:  Headache       Date:  2014-04       Impact factor: 5.887

Review 6.  The role of purinergic signaling in the etiology of migraine and novel antimigraine treatment.

Authors:  Marek Cieślak; Joanna Czarnecka; Katarzyna Roszek; Michał Komoszyński
Journal:  Purinergic Signal       Date:  2015-05-10       Impact factor: 3.765

7.  P2X7 receptors exert a permissive effect on the activation of presynaptic AMPA receptors in rat trigeminal caudal nucleus glutamatergic nerve terminals.

Authors:  Diego Currò; Pierluigi Navarra; Irene Samengo; Maria Martire
Journal:  J Headache Pain       Date:  2020-07-02       Impact factor: 7.277

Review 8.  A link between gastrointestinal disorders and migraine: Insights into the gut-brain connection.

Authors:  Sheena K Aurora; Stephen B Shrewsbury; Sutapa Ray; Nada Hindiyeh; Linda Nguyen
Journal:  Headache       Date:  2021-04-01       Impact factor: 5.887

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.